This website uses cookies. By using the site you are agreeing to our Privacy Policy.

Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.


Main menu starts here.
Skip the main menu to current location in your website.

Current location in your website.
Skip to main contents.


What's New

 

The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.

FUJIFILM Toyama Chemical enters agreement with Appili Therapeutics regarding the assignment of rights for the development and marketing of T-2307, a candidate compound for the treatment of fungal diseases.
November 21, 2019
FUJIFILM Toyama Chemical Co., Ltd.

Tokyo, November 21, 2019 ― FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada) announced today it has entered an agreement with Appili Therapeutics (“Appili”) regarding the assignment of rights for the development and marketing of T-2307 outside of Japan. Subject to terms of the agreement, FUJIFILM Toyama Chemical will transfer the development and marketing rights of the compound to Appili and receive milestones payments as well as royalties in the future.

T-2307, an antifungal candidate compound developed by FUJIFILM Toyama Chemical, exhibits it’s antifungal activity through a novel mode of action whereby it actively accumulates in fungal cells*1 and is designed to selectively disrupt the function of fungal mitochondria*2.

In the course of R&D with primary focus of targeting fungi, FUJIFILM Toyama Chemical has discovered and developed T-2307 for the treatment of various mycoses*3 including those due to drug resistant strains. The company continued to conduct clinical development of T-2307, including Phase I clinical trials in the United States.

Appili established in 2015 in Canada, is engaged in the R&D of drugs specializing in the area of infectious diseases. The company was listed in July 2019 on the Toronto Stock Exchange, and has been accelerating the development of new drugs. Through conclusion of this agreement, Appili plans to carry out a Phase II clinical trial of T-2307 targeting cryptococcal meningitis*4, a disease for which an effective treatment drug is being sought.

FUJIFILM Toyama Chemical has been promoting the R&D of treatment drugs with unique mode of action, focusing on “infectious diseases” as one of the key areas.

The agreement will contribute to solving social issues through the provision of innovative and high value-added drugs through the cooperation of Appili and FUJIFILM Toyama Chemical and also would widen the physician’s choice by treating fungal infections as well as the treatment options of the patient.

* 1 Microorganisms called "mold" or "yeast". The majority of funguses is harmless to healthy individuals, but may cause mycoses in immunocompromised conditions.

* 2 Organelles found in most eukaryotic cells. Mitochondria are membrane-bound cell organelles that generate most of the chemical energy needed to power the cell's biochemical reactions.

* 3 An infection caused by a fungus that enters deep areas of the body such as the lungs, liver and the brain. It is a type of opportunistic infection, caused by pathogens that do not occur in healthy individuals, but develop in patients whose immune system has declined because of immunocompromised condition in case of bone marrow or organ transplants, long term administration of steroids and/or HIV/AIDS. It is caused by fungus species such as Candida, Aspergillus, and Cryptococcus.

* 4 Cerebral meningitis caused by Cryptococcus species. Under immunocompromised conditions, cryptococcal fungal cells that penetrate from the respiratory organs through the blood stream and enter the cerebrospinal fluid, causing inflammation of the membranes covering the spinal cord and brain. In August 2018, the U.S. FDA added cryptococcal meningitis as a tropical infectious disease requiring the development of treatment drugs, and established a program to promote drug development (Priority Review Voucher: The right to guarantee priority review at the time of filing applications for approval).


About FUJIFILM Toyama Chemical

FUJIFILM Toyama Chemical was launched by merging FUJIFILM RI Pharma Co., Ltd., a company that conducts research, development, manufacture, and sales of radiopharmaceuticals, and TOYAMA CHEMICAL CO., LTD., a company that conducts research, development, manufacture, and sales of small molecule pharmaceutical products. FUJIFILM Toyama Chemical dedicates efforts to developing innovative diagnostic and therapeutic radiopharmaceuticals and therapeutic drugs with unique action mechanisms in the fields of “oncology”, “central nervous system diseases”, and “infectious diseases” where significant unmet medical needs still exist, under close collaboration with FUJIFILM Corporation, which focuses on research of new medicines. The joining of FUJIFILM Toyama Chemical’s and Fujifilm’ know-how will also advance the development of new medicines utilizing drug delivery system (DDS) technologies that deliver the required amount of a drug in a timely manner to a specific body area. Also, by exploring synergy with in vitro diagnostic (IVD) devices and reagents owned by Fujifilm group companies, the company will expand its offering of comprehensive solutions from “diagnosis” to “treatment”.

For more information of FUJIFILM Toyama Chemical, please visit http://fftc.fujifilm.co.jp/en/


About Appili Therapeutics

Appili Therapeutics Inc. was founded to advance the global fight against infectious disease by matching clearly defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors, and society face in this challenging disease space. Appili has built a pipeline of assets designed to address a broad range of significant unmet medical needs in the infectious disease landscape. This diverse pipeline aims to address some of the most urgent threats in global public health. Via an in-licensing program, Appili acquired the rights to ATI-1701, a vaccine for tularemia, that it is developing to mitigate the risks of a very serious biological weapons threat. ATI-1503 is a drug discovery program aimed at generating negamycin analogue candidates, which are a novel class of antibiotics with broad-spectrum activity against Gram-negative superbugs. ATI-1501 employs Appili’s proprietary, taste-masked, oral-suspension technology with metronidazole for the growing number of patients with difficulty swallowing. Headquartered in Halifax, Nova Scotia, with offices in Mississauga, Ontario, Appili is pursuing worldwide opportunities in collaboration with science and industry commercial partners, governments and government agencies. For more information, visit www.AppiliTherapeutics.com.

Footer starts here.

Pages ends here.
Move to top of the page.